Elsevier

Ophthalmology

Volume 103, Issue 5, May 1996, Pages 768-775
Ophthalmology

Systemic Drug Toxicity Trends in immunosuppressive Therapy of Immune and Inflammatory Ocular Disease

https://doi.org/10.1016/S0161-6420(96)30618-0Get rights and content

Abstract

Purpose: To compare the relative toxicities of six systemic immunosuppressive drugs and systemic corticosteroids used to treat patients with severe ocular inflammatory disease and to identify factors influencing their occurrence.

Methods: The authors reviewed the clinical records of 602 patients with ocular inflammatory disease treated with immunosuppressive drug therapy and/or systemic corticosteroids for adverse systemic effects while undergoing therapy. Proportional hazards regression analysis was performed to identify demographic and clinical factors that influence the occurrence of drug toxicity in these patients.

Results: Immunosuppressive drug treatment was more likely to result in discontinuation of therapy because of toxic side effects than was corticosteroid treatment. However, unlike many of the side effects of corticosteroid treatment, the side effects of immunosuppressive therapy were reversible with reduction in dosage or discontinuation of the drug. Gastrointestinal symptoms and hematologic abnormalities accounted for the majority of reported side effects of the immunosuppressive medications. Neuropsychiatric and endocrine side effects were common in patients taking prednisone. In 17 patients treated with prednisone, pathologic fractures developed, which involved the hips and the spine. Female sex and age older than 60 years also were identified as factors associated with intolerance to drug therapy in the authors' study population. Race and type of systemic and ocular disease were not significant factors influencing tolerance to drug therapy.

Conclusion: These findings suggest that when properly administered and monitored for adverse effects, most immunosuppressive agents used in the current study have similar risk profiles with relatively few serious therapeutic mishaps and largely reversible side effects. In contrast, corticosteroids can result in permanent disabilities as a result of long-term treatment.

References (41)

  • GB Klintmalm et al.

    Nephrotoxicity of cyclosporin A in liver and kidney transplant patients

    Lancet

    (1981)
  • WJ Shergy et al.

    Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis

    Am J Med

    (1988)
  • B Amor et al.

    Chlorambucil in rheumatoid arthritis

    Clin Rheum Dis

    (1980)
  • R Hemady et al.

    Immunosuppressive drugs in immune and inflammatory ocular disease [published erratum appears in Surv Ophthalmol 1991 May-June; 35:475]

    Surv Ophthalmol

    (1991)
  • J Santamaria

    Steroidal agents: their systemic and ocular complications

    Ocular Inflammation and Therapeutics

    (1983)
  • AS Fauci et al.

    Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years

    Ann Intern Med

    (1983)
  • RB Nussenblatt et al.

    Effectiveness of cyclosporine therapy for Behcet's disease

    Arthritis Rheum

    (1985)
  • JH Elliott et al.

    Behcet's syndrome: treatment with chlorambucil

    Trans Am Ophthalmol Soc

    (1984)
  • RJ McKendry et al.

    Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A case-control study of 131 patients

    Arch Intern Med

    (1989)
  • G Singh et al.

    Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective

    Arthritis Rheum

    (1989)
  • Cited by (0)

    View full text